Details of the Drug Combination

General Information of Drug Combination (ID: DCC7TWY)

Drug Combination Name
10-hydroxycamptothecin Ridaforolimus
Indication
Disease Entry Status REF
Breast and ovarian cancer syndrome Investigative [1]
Component Drugs 10-hydroxycamptothecin   DM9WLN4 Ridaforolimus   DMLHEU7
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: UWB1289
Zero Interaction Potency (ZIP) Score: 4.18
Bliss Independence Score: 3.85
Loewe Additivity Score: 4.52
LHighest Single Agent (HSA) Score: 7.54

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of 10-hydroxycamptothecin
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
10-hydroxycamptothecin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
10-hydroxycamptothecin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [4]
------------------------------------------------------------------------------------
10-hydroxycamptothecin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Response To Substance [5]
------------------------------------------------------------------------------------
Indication(s) of Ridaforolimus
Disease Entry ICD 11 Status REF
Sarcoma 2A60-2C35 Phase 3 [3]
Ridaforolimus Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DC1RUS2 NCIH2122 Investigative [7]
Adenocarcinoma DCT9ZFR NCIH520 Investigative [7]
Adenocarcinoma DC0L68I HT29 Investigative [7]
Amelanotic melanoma DC4X7ZW A2058 Investigative [7]
Mesothelioma DCJ4JQG MSTO Investigative [7]
Non small cell carcinoma DCZ1UER SKMES1 Investigative [7]
Ovarian serous cystadenocarcinoma DCYP0SO SK-OV-3 Investigative [7]
Prostate carcinoma DCKTR1W LNCAP Investigative [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
2 Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. Int J Oncol. 1998 Apr;12(4):793-804.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7884).
4 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
5 siRNA-mediated Bcl-2 and Bcl-xl gene silencing sensitizes human hepatoblastoma cells to chemotherapeutic drugs. Clin Exp Pharmacol Physiol. 2007 May-Jun;34(5-6):450-6. doi: 10.1111/j.1440-1681.2007.04593.x.
6 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
7 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976